Baseline patient and disease characteristics
| . | All patients (n = 231) . | High risk (n = 74) . | Intermediate risk (n = 28) . | Favorable risk (n = 43) . | Uninformative (n = 86) . | P . |
|---|---|---|---|---|---|---|
| Age (y), median (range) | 12 (1-29) | 11 (1-29) | 9 (2-22) | 12 (4-29) | 13 (2-27) | .047 |
| Age categories, n (%) | ||||||
| <3 y | 12 (5.2%) | 8 (11%) | 2 (7.1%) | 0 (0%) | 2 (2.3%) | .015 |
| 3-9.99 y | 81 (35%) | 23 (31%) | 15 (54%) | 14 (33%) | 29 (34%) | |
| 10-17.99 y | 100 (43%) | 29 (39%) | 10 (36%) | 25 (58%) | 36 (42%) | |
| ≥18 y | 38 (16%) | 14 (19%) | 1 (3.6%) | 4 (9.3%) | 19 (22%) | |
| Male n (%) | 134 (58%) | 49 (66%) | 10 (36%) | 28 (65%) | 47 (55%) | .029 |
| Prior HSCT | 100 (43%) | 38 (51%) | 12 (43%) | 14 (33%) | 36 (42%) | .26 |
| Prior blinatumomab | 24 (10%) | 9 (12%) | 7 (25%) | 2 (4.7%) | 6 (7.0%) | .040 |
| Refractory at referral | 91 (39%) | 30 (41%) | 10 (36%) | 17 (40%) | 34 (40%) | .98 |
| Disease status at referral | ||||||
| Primary refractory | 39 (17%) | 18 (24%) | 2 (7.1%) | 3 (7.0%) | 16 (19%) | .077 |
| 1st relapse | 69 (36%) | 20 (27%) | 12 (43%) | 10 (23%) | 27 (31%) | |
| 2nd or greater relapse | 123 (64%) | 36 (49%) | 14 (50%) | 30 (70%) | 43 (50%) | |
| Marrow status preinfusion | ||||||
| <0.01% | 87 (38%) | 34 (46%) | 7 (25%) | 17 (40%) | 29 (34%) | .18 |
| 0.01-4.99% | 46 (20%) | 16 (22%) | 3 (11%) | 6 (14%) | 21 (24%) | |
| 5-24.99% | 21 (9.1%) | 4 (5.4%) | 3 (11%) | 6 (14%) | 8 (9.3%) | |
| ≥25% | 77 (33%) | 20 (27%) | 15 (54%) | 14 (33%) | 28 (33%) |
| . | All patients (n = 231) . | High risk (n = 74) . | Intermediate risk (n = 28) . | Favorable risk (n = 43) . | Uninformative (n = 86) . | P . |
|---|---|---|---|---|---|---|
| Age (y), median (range) | 12 (1-29) | 11 (1-29) | 9 (2-22) | 12 (4-29) | 13 (2-27) | .047 |
| Age categories, n (%) | ||||||
| <3 y | 12 (5.2%) | 8 (11%) | 2 (7.1%) | 0 (0%) | 2 (2.3%) | .015 |
| 3-9.99 y | 81 (35%) | 23 (31%) | 15 (54%) | 14 (33%) | 29 (34%) | |
| 10-17.99 y | 100 (43%) | 29 (39%) | 10 (36%) | 25 (58%) | 36 (42%) | |
| ≥18 y | 38 (16%) | 14 (19%) | 1 (3.6%) | 4 (9.3%) | 19 (22%) | |
| Male n (%) | 134 (58%) | 49 (66%) | 10 (36%) | 28 (65%) | 47 (55%) | .029 |
| Prior HSCT | 100 (43%) | 38 (51%) | 12 (43%) | 14 (33%) | 36 (42%) | .26 |
| Prior blinatumomab | 24 (10%) | 9 (12%) | 7 (25%) | 2 (4.7%) | 6 (7.0%) | .040 |
| Refractory at referral | 91 (39%) | 30 (41%) | 10 (36%) | 17 (40%) | 34 (40%) | .98 |
| Disease status at referral | ||||||
| Primary refractory | 39 (17%) | 18 (24%) | 2 (7.1%) | 3 (7.0%) | 16 (19%) | .077 |
| 1st relapse | 69 (36%) | 20 (27%) | 12 (43%) | 10 (23%) | 27 (31%) | |
| 2nd or greater relapse | 123 (64%) | 36 (49%) | 14 (50%) | 30 (70%) | 43 (50%) | |
| Marrow status preinfusion | ||||||
| <0.01% | 87 (38%) | 34 (46%) | 7 (25%) | 17 (40%) | 29 (34%) | .18 |
| 0.01-4.99% | 46 (20%) | 16 (22%) | 3 (11%) | 6 (14%) | 21 (24%) | |
| 5-24.99% | 21 (9.1%) | 4 (5.4%) | 3 (11%) | 6 (14%) | 8 (9.3%) | |
| ≥25% | 77 (33%) | 20 (27%) | 15 (54%) | 14 (33%) | 28 (33%) |